Therapeutic efficacy of cell carrier–delivered oncolytic measles virotherapy in a Nalm-6 disseminated model of precursor B-ALL. (A) Kaplan-Meier survival curves of mice bearing disseminated Nalm 6 xenografts treated intravenously with a total of either 1 × 106 pfu MV-NSe; 1 × 106 BM-MSCs loaded with MV-NSe at MOI of 1.0, or 1 × 106 uninfected BM-MSCs. Mice in the relevant groups also received 50 IU (100 μL) of anti-MV IgG antibody (or 100 μL PBS control) via the intraperitoneal route 3 hours before each MV injection. Data represent results from 3 independent experiments. N = 2 to 5 per group. (B) Representative bioluminescence images of SCID mice treated with naked MV, MV-infected BM-MSCs, or BM-MSCs alone in the presence or absence of anti-measles antibody–containing serum. The images demonstrate disease burden after ALL cell injection at 6, 9, and 12 weeks. Where no image is shown, this indicates that no mice remained in the relevant treatment group. (C) Scatter dot plot showing individual values for luminescent activity (photons per second) performed on each surviving animal in each treatment group at week 6. Values are represented minus background luminescent activity. Data are shown as mean ± SEM. To ensure that data for all surviving animals could be plotted, zero or negative values were arbitrarily assigned a value of 1.0. **P = .0051.
